Business Wire

GEMALTO

6.3.2019 07:02:16 CET | Business Wire | Press release

Share
Gemalto Expands Cloud HSM On Demand Solutions

Gemalto, the world leader in digital security, today announced the availability of three new cloud-based Hardware Security Module (HSM) services, HSM On Demand for CyberArk , HSM On Demand for Hyperledger and HSM On Demand for Oracle TDE . Each service is available through the SafeNet Data Protection on Demand platform, a marketplace of cloud-based HSM, encryption and key management services that easily integrates with most widely used cloud services and IT products to protect data wherever it is created, accessed or stored.

The rapid adoption of cloud and digital services has made it difficult for organizations to secure data and identities that are created, stored and managed outside the perimeter. While organizations recognize that data encryption is the optimal solution to secure sensitive information, they can be challenged by the cost and complexity of deploying encryption, including Hardware Security Modules to secure their cryptographic operations. Gemalto’s SafeNet Data Protection On Demand solves these challenges by providing cloud-based HSM services that and can be deployed in minutes without the need for highly skilled staff. Gemalto, a leader in the HSM market, is proven to help customers secure their encryption keys and data across cloud, hybrid, and on-premises environments.

“A worsening threat landscape, combined with aggressive cloud adoption and evolving privacy regulations, have presented complex new challenges related to encryption, privileged access and financial transactions,” said Todd Moore, Senior Vice President of Encryption Products at Gemalto. “Our newest Cloud HSM On Demand services help organizations stay in front of new threats and regulations, by easily deploying an HSM solution for the strongest possible key management and security practices, all while providing fast, easy set-up, with remarkable savings over traditional approaches involving specialized hardware and skills.”

“Many organizations would like to deploy data security more broadly, but are often wary due to concerns about complexity, cost and staffing requirements, particularly with respect to encryption and key management,” said Garrett Bekker, Principal Analyst at 451 Research. “The release of SafeNet Data Protection On Demand was a positive step towards addressing those concerns, and extending its cloud HSM capability to newer use cases like blockchain, database security and privileged credentials is a logical and timely move.”

HSM On Demand for CyberArk
HSM On Demand for CyberArk works seamlessly with CyberArk’s Privileged Access Security Solution, providing private key protection and strong entropy for key generation for system keys.. By securing the master key and ensuring that it is hosted in a secure vault, HSM On Demand for CyberArk mitigates the risk of the master key being exposed or compromised.

HSM On Demand for Hyperledger
HSM On Demand for Hyperledger provides trust for blockchain transactions by securing the cryptographic keys that sign them. It protects digital wallets, while ensuring keys are readily available in the cloud once access is granted. The service provides high assurance security in data centers and the cloud, enabling multi-tenancy of blockchain identities per partition as proof of transaction and for auditing requirements. It also delivers performance improvements resulting from off-loading cryptographic operations from application servers to the HSM on Demand service.

HSM On Demand for Oracle TDE
HSM for Oracle TDE (Transparent Data Encryption) solves the challenge presented by locally stored encryption keys by protecting them with a master key, stored in a separate service key vault. This ensures that only authorized services are allowed to request the local key to be decrypted. If an attacker steals the database, it is encrypted and inaccessible, since the attacker does not have access to the keys that are securely stored on the HSM.

Additional Resources

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2018 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.

From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.

Our 15,000 employees operate out of 110 offices, 47 personalization and data centers, and 35 research and software development centers located in 47 countries.

For more information visit www.gemalto.com , or follow @gemalto on Twitter.

Contact:

Gemalto media contacts: Tauri Cox North America +1 512 257 3916 tauri.cox@gemalto.com

Sophie Dombres Europe Middle East & Africa +33 4 42 36 57 38 sophie.dombres@gemalto.com

Jaslin Huang Asia Pacific +65 6317 3005 jaslin.huang@gemalto.com

Alexis Camarillo Latin America +52 5521223627 alexis.camarillo@gemalto.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye